Mediplantex National Pharmaceutical JSC (HNX:MED)
Vietnam
· Delayed Price · Currency is VND 22,800
0.00 (0.00%)
At close: Aug 7, 2025
HNX:MED Cash Flow Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Net Income | 15,247 | 11,744 | 6,366 | 3,747 | 24,422 | Upgrade
|
| Depreciation & Amortization | 7,916 | 8,444 | 10,020 | 9,536 | 10,020 | Upgrade
|
| Loss (Gain) From Sale of Assets | -773.89 | -6,395 | -3,782 | -3,902 | -4,102 | Upgrade
|
| Other Operating Activities | 2,015 | -1,936 | 1,683 | -2,016 | -3,885 | Upgrade
|
| Change in Accounts Receivable | 23,261 | 37,508 | 2,063 | 58,829 | 63,652 | Upgrade
|
| Change in Inventory | 15,425 | -1,583 | -14,664 | 4,843 | 39,261 | Upgrade
|
| Change in Accounts Payable | -16,803 | -95,351 | 26,049 | -6,766 | -42,537 | Upgrade
|
| Change in Other Net Operating Assets | 1,368 | 3,660 | -1,503 | -2,160 | 2,524 | Upgrade
|
| Operating Cash Flow | 47,653 | -43,908 | 26,231 | 62,110 | 89,354 | Upgrade
|
| Operating Cash Flow Growth | - | - | -57.77% | -30.49% | -23.00% | Upgrade
|
| Capital Expenditures | -9,979 | -40,594 | -117,270 | -54,364 | -28,827 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 43.64 | 240.21 | 992.27 | 8.18 | Upgrade
|
| Investment in Securities | 8,000 | 72,400 | -44,000 | 6,000 | - | Upgrade
|
| Other Investing Activities | 1,121 | 7,204 | 3,354 | 3,479 | 3,376 | Upgrade
|
| Investing Cash Flow | -858.42 | 39,054 | -157,676 | -43,893 | -54,843 | Upgrade
|
| Short-Term Debt Issued | 157,753 | 193,594 | 205,142 | 180,305 | 218,086 | Upgrade
|
| Total Debt Issued | 157,753 | 193,594 | 205,142 | 180,305 | 218,086 | Upgrade
|
| Short-Term Debt Repaid | -194,430 | -219,966 | -182,973 | -192,316 | -233,080 | Upgrade
|
| Total Debt Repaid | -194,430 | -219,966 | -182,973 | -192,316 | -233,080 | Upgrade
|
| Net Debt Issued (Repaid) | -36,676 | -26,372 | 22,168 | -12,012 | -14,995 | Upgrade
|
| Issuance of Common Stock | - | - | 153,104 | - | - | Upgrade
|
| Common Dividends Paid | -11,021 | -6,426 | -8,816 | -13,281 | -9,307 | Upgrade
|
| Financing Cash Flow | -47,697 | -32,799 | 166,456 | -25,293 | -24,302 | Upgrade
|
| Foreign Exchange Rate Adjustments | -19.53 | 2.9 | -28.96 | - | 10.42 | Upgrade
|
| Net Cash Flow | -922.47 | -37,650 | 34,983 | -7,076 | 10,219 | Upgrade
|
| Free Cash Flow | 37,674 | -84,502 | -91,039 | 7,746 | 60,527 | Upgrade
|
| Free Cash Flow Growth | - | - | - | -87.20% | -38.65% | Upgrade
|
| Free Cash Flow Margin | 8.50% | -20.98% | -22.70% | 2.25% | 11.61% | Upgrade
|
| Free Cash Flow Per Share | 3035.74 | -6809.19 | -9696.32 | 1234.13 | 9638.35 | Upgrade
|
| Cash Interest Paid | 3,816 | 5,432 | 4,953 | 3,643 | 4,302 | Upgrade
|
| Cash Income Tax Paid | 3,874 | 4,719 | 272.58 | 2,383 | 9,020 | Upgrade
|
| Levered Free Cash Flow | 29,827 | -101,170 | -115,881 | 14,442 | 45,357 | Upgrade
|
| Unlevered Free Cash Flow | 32,195 | -97,798 | -112,754 | 16,703 | 48,992 | Upgrade
|
| Change in Working Capital | 23,250 | -55,765 | 11,945 | 54,746 | 62,900 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.